Author MStranslate

Last week, we posted on Facebook that the FDA has decided to not approve tolebrutinib for the treatment of secondary progressive multiple sclerosis, despite positive Phase 3 trial results.  In this article,...

2026 is upon us!  As fireworks ring out around the world to usher in the new year, we like to look ahead and think about what new developments we might see in multiple sclerosis research over the coming 12...

Between September 23 and 26, 2025, the 41st annual ECTRIMS Congress took place in Barcelona, Spain, co-convened by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and...

Prior to the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022, held in Amsterdam, The Netherlands, we announced that our co-founder, Brett Drummond, had been invited...

As many will be aware, MStranslate has had the privilege of partnering with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) since 2022. The ECTRIMS Podcast This close...

In approximately 3 weeks, we will be celebrating World Multiple Sclerosis Day.  The theme in 2025 is ‘Navigating MS Together’, which perfectly aligns with everything that we stand for at MStranslate.  In...

Research Summary: A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective...

Research Summary: Senolytic treatment diminishes microglia and decreases severity of experimental autoimmune encephalomyelitis While we now have a number of treatments for multiple sclerosis, there is still...

The MStranslate team recently attended the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2024, held in Copenhagen, Denmark, between September 17 and 20. As he has...

Research Summary: Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease Researchers are constantly looking at novel approaches for the treatment of...